Patient characteristics and their association with additional CAs
| Characteristics . | Patients with CAs, n=21 . | Patients without CAs, n=237 . | P . |
|---|---|---|---|
| Median age, y (range) | 57 (31-81) | 47 (15-84) | .03 |
| Splenomegaly, no. (%) | 5 (24) | 65 (27) | .72 |
| Hemoglobin level, median g/L (range) | 130 (85-167) | 124 (62-158) | .38 |
| Platelet count, median × 109/L (range) | 366 (128-1290) | 365 (100-1476) | .92 |
| Leukocyte count, median × 109/L (range) | 26.2 (4.7-277) | 45 (2.2-283) | .28 |
| Basophils in PB, median % (range) | 3 (1-19) | 3 (0-19) | .96 |
| Blasts in PB, median % (range) | 0 (0-7) | 0 (0-12) | .84 |
| Blasts in BM, median % (range) | 2 (0-6) | 2 (0-14) | .32 |
| Basophils in BM, median % (range) | 3 (0-8) | 2 (0-15) | .17 |
| Sokal index, no. (%) | |||
| Low | 12 (57) | 153 (65) | — |
| Intermediate | 5 (24) | 66 (28) | — |
| High | 4 (19) | 18 (8) | 2 |
| Hasford index, no. (%) | |||
| Low | 9 (43) | 141 (59) | — |
| Intermediate | 10 (48) | 89 (38) | — |
| High | 2 (9) | 7 (3) | .15 |
| Ph-positive metaphases more than 90%, no. (%) | 20 (95) | 218 (92) | .21 |
| Imatinib dose, no. (%) | |||
| 800 mg | 13 (62) | 195 (82) | — |
| 400 mg | 8 (38) | 42 (38) | .02 |
| Clonal evolution, no. (%) | 0 (0) | 8 (3) | .39 |
| Grades 3–4 myelosuppression, no. (%) | |||
| Anemia | 5 (24) | 26 (11) | .15 |
| Neutropenia | 7 (33) | 84 (35) | .99 |
| Thrombocytopenia | 9 (43) | 55 (23) | .06 |
| Characteristics . | Patients with CAs, n=21 . | Patients without CAs, n=237 . | P . |
|---|---|---|---|
| Median age, y (range) | 57 (31-81) | 47 (15-84) | .03 |
| Splenomegaly, no. (%) | 5 (24) | 65 (27) | .72 |
| Hemoglobin level, median g/L (range) | 130 (85-167) | 124 (62-158) | .38 |
| Platelet count, median × 109/L (range) | 366 (128-1290) | 365 (100-1476) | .92 |
| Leukocyte count, median × 109/L (range) | 26.2 (4.7-277) | 45 (2.2-283) | .28 |
| Basophils in PB, median % (range) | 3 (1-19) | 3 (0-19) | .96 |
| Blasts in PB, median % (range) | 0 (0-7) | 0 (0-12) | .84 |
| Blasts in BM, median % (range) | 2 (0-6) | 2 (0-14) | .32 |
| Basophils in BM, median % (range) | 3 (0-8) | 2 (0-15) | .17 |
| Sokal index, no. (%) | |||
| Low | 12 (57) | 153 (65) | — |
| Intermediate | 5 (24) | 66 (28) | — |
| High | 4 (19) | 18 (8) | 2 |
| Hasford index, no. (%) | |||
| Low | 9 (43) | 141 (59) | — |
| Intermediate | 10 (48) | 89 (38) | — |
| High | 2 (9) | 7 (3) | .15 |
| Ph-positive metaphases more than 90%, no. (%) | 20 (95) | 218 (92) | .21 |
| Imatinib dose, no. (%) | |||
| 800 mg | 13 (62) | 195 (82) | — |
| 400 mg | 8 (38) | 42 (38) | .02 |
| Clonal evolution, no. (%) | 0 (0) | 8 (3) | .39 |
| Grades 3–4 myelosuppression, no. (%) | |||
| Anemia | 5 (24) | 26 (11) | .15 |
| Neutropenia | 7 (33) | 84 (35) | .99 |
| Thrombocytopenia | 9 (43) | 55 (23) | .06 |
CA indicates cytogenetic abnormalities; PB, peripheral blood; BM, bone marrow; and —, not applicable.